These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 28183255)

  • 1. Melanoma Adjuvant Treatment: Current Insight and Clinical Features.
    D'Aniello C; Perri F; Scarpati GDV; Pepa CD; Pisconti S; Montesarchio V; Wernert N; Zarone MR; Caraglia M; Facchini G; Berretta M; Cavaliere C
    Curr Cancer Drug Targets; 2018; 18(5):442-456. PubMed ID: 28183255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant therapy in melanoma.
    Mohr P; Weichenthal M; Hauschild A
    Onkologie; 2003 Jun; 26(3):227-33. PubMed ID: 12845206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis.
    Mocellin S; Pasquali S; Rossi CR; Nitti D
    J Natl Cancer Inst; 2010 Apr; 102(7):493-501. PubMed ID: 20179267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. (Neo)adjuvant systemic therapy for melanoma.
    van Zeijl MC; van den Eertwegh AJ; Haanen JB; Wouters MW
    Eur J Surg Oncol; 2017 Mar; 43(3):534-543. PubMed ID: 27453302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ulceration as a predictive marker for response to adjuvant interferon therapy in melanoma.
    McMasters KM; Edwards MJ; Ross MI; Reintgen DS; Martin RC; Urist MM; Noyes RD; Sussman JJ; Stromberg AJ; Scoggins CR
    Ann Surg; 2010 Sep; 252(3):460-5; discussion 465-6. PubMed ID: 20739846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991.
    Eggermont AM; Suciu S; Testori A; Kruit WH; Marsden J; Punt CJ; Santinami M; Salès F; Schadendorf D; Patel P; Dummer R; Robert C; Keilholz U; Yver A; Spatz A
    Eur J Cancer; 2012 Jan; 48(2):218-25. PubMed ID: 22056637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma.
    Verma S; Quirt I; McCready D; Bak K; Charette M; Iscoe N
    Cancer; 2006 Apr; 106(7):1431-42. PubMed ID: 16511841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The 2017 complete overhaul of adjuvant therapies for high-risk melanoma and its consequences for staging and management of melanoma patients.
    Eggermont AMM; Dummer R
    Eur J Cancer; 2017 Nov; 86():101-105. PubMed ID: 28968566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. It is finally time for adjuvant therapy in melanoma.
    Napolitano S; Brancaccio G; Argenziano G; Martinelli E; Morgillo F; Ciardiello F; Troiani T
    Cancer Treat Rev; 2018 Sep; 69():101-111. PubMed ID: 29957365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Adjuvant systemic treatment of melanoma].
    Kähler KC; Egberts F; Hauschild A; Mohr P
    Hautarzt; 2011 Jun; 62(6):414, 416-22. PubMed ID: 21656113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant Therapy for Melanoma.
    Agha A; Tarhini AA
    Curr Oncol Rep; 2017 May; 19(5):36. PubMed ID: 28417343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Final Results of the Sunbelt Melanoma Trial: A Multi-Institutional Prospective Randomized Phase III Study Evaluating the Role of Adjuvant High-Dose Interferon Alfa-2b and Completion Lymph Node Dissection for Patients Staged by Sentinel Lymph Node Biopsy.
    McMasters KM; Egger ME; Edwards MJ; Ross MI; Reintgen DS; Noyes RD; Martin RC; Goydos JS; Beitsch PD; Urist MM; Ariyan S; Sussman JJ; Davidson BS; Gershenwald JE; Hagendoorn LJ; Stromberg AJ; Scoggins CR
    J Clin Oncol; 2016 Apr; 34(10):1079-86. PubMed ID: 26858331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of adjuvant systemic therapy in melanoma.
    Eggermont AM; Testori A; Marsden J; Hersey P; Quirt I; Petrella T; Gogas H; MacKie RM; Hauschild A
    Ann Oncol; 2009 Aug; 20 Suppl 6(Suppl 6):vi30-4. PubMed ID: 19617295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant ipilimumab in stage III melanoma: New landscape, new questions.
    Eggermont AM
    Eur J Cancer; 2016 Dec; 69():39-42. PubMed ID: 27816830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pros and cons of adjuvant interferon in the treatment of melanoma.
    Sabel MS; Sondak VK
    Oncologist; 2003; 8(5):451-8. PubMed ID: 14530498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant therapy for melanoma.
    Sondak VK
    Cancer J; 2001; 7 Suppl 1():S24-7. PubMed ID: 11504282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New drugs in melanoma: it's a whole new world.
    Eggermont AM; Robert C
    Eur J Cancer; 2011 Sep; 47(14):2150-7. PubMed ID: 21802280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of adjuvant therapy in melanoma management.
    Barth A; Morton DL
    Cancer; 1995 Jan; 75(2 Suppl):726-34. PubMed ID: 7805001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Detection of residual microscopic disease in melanoma: interest of the sentinel lymph node procedure?].
    Mateus C; Thomas M; Robert C
    Bull Cancer; 2014 Apr; 101(4):354-7. PubMed ID: 24793626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant high-dose interferon-alpha therapy for high-risk melanoma.
    Kirkwood JM; Tarhini AA
    Forum (Genova); 2003; 13(2):127-40; quiz 187-8. PubMed ID: 14732880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.